Clinical Trials Browser

capmatinib × 1 year × Clear all

Carcinoma, Non-Small-Cell Lung

NCT05642572 2026-06-03

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Phase 2 Recruiting

66 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05703516 2026-06-01

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Recruiting

44 enrolled

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03784014 2026-04-29

MULTISARC

Phase 3 Completed

603 enrolled

Sarcoma

Neoplasm Metastasis, Sarcoma

NCT05110196 2026-04-07

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Phase 4 Completed

50 enrolled

Thoracic

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03040973 2026-04-02

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Phase 2 Active not recruiting

29 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04677595 2026-03-31

GeoMETry-C

Phase 2 Completed

36 enrolled 26 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04741789 2026-03-16

Managed Access Programs for INC280, Capmatinib

No longer available

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

472 enrolled

Tumor-Agnostic

Neoplasms

NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Phase 1 Active not recruiting

105 enrolled

Thoracic

EGFR-mutant Non-small Cell Lung Cancer

NCT05722886 2025-11-24

DETERMINE

Phase 2/3 Recruiting

825 enrolled

LymphoidOther hematologic neoplasm

Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

NCT06988475 2025-11-24

DETERMINE

Phase 2/3 Recruiting

30 enrolled

CNSGastrointestinalOther hematologic neoplasmSarcoma

Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neuroblastoma, Sarcoma, Stomach Neoplasms, Hematologic Neoplasms

NCT04926831 2025-10-16

Geometry-N

Phase 2 Terminated

4 enrolled 10 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04575025 2025-09-15

Special Drug Use-results Surveillance of Tabrecta Tablets

Completed

109 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

METalmark

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

MULTISARC

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

GeoMETry-C

Managed Access Programs for INC280, Capmatinib

ESMART

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

DETERMINE

DETERMINE

Geometry-N

Special Drug Use-results Surveillance of Tabrecta Tablets